Anixa Biosciences (ANIX) Competitors $2.75 -0.10 (-3.51%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. ETON, ALLO, TRDA, AMLX, ALT, HRTX, RGNX, VERV, TECX, and ORKAShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Eton Pharmaceuticals (ETON), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Amylyx Pharmaceuticals (AMLX), Altimmune (ALT), Heron Therapeutics (HRTX), REGENXBIO (RGNX), Verve Therapeutics (VERV), Tectonic Therapeutic (TECX), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Eton Pharmaceuticals Allogene Therapeutics Entrada Therapeutics Amylyx Pharmaceuticals Altimmune Heron Therapeutics REGENXBIO Verve Therapeutics Tectonic Therapeutic Oruka Therapeutics Eton Pharmaceuticals (NASDAQ:ETON) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Do insiders and institutionals have more ownership in ETON or ANIX? 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 14.9% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 25.3% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor ETON or ANIX? Eton Pharmaceuticals received 66 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 76.19% of users gave Anixa Biosciences an outperform vote while only 65.77% of users gave Eton Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEton PharmaceuticalsOutperform Votes9865.77% Underperform Votes5134.23% Anixa BiosciencesOutperform Votes3276.19% Underperform Votes1023.81% Does the media favor ETON or ANIX? In the previous week, Anixa Biosciences had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 5 mentions for Anixa Biosciences and 4 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.70 beat Anixa Biosciences' score of 0.19 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ETON or ANIX? Eton Pharmaceuticals has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Do analysts recommend ETON or ANIX? Eton Pharmaceuticals currently has a consensus target price of $27.67, indicating a potential upside of 96.50%. Anixa Biosciences has a consensus target price of $9.00, indicating a potential upside of 227.27%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is ETON or ANIX more profitable? Anixa Biosciences has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. Eton Pharmaceuticals' return on equity of -36.29% beat Anixa Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Eton Pharmaceuticals-15.81% -36.29% -16.84% Anixa Biosciences N/A -58.55%-53.29% Which has higher valuation & earnings, ETON or ANIX? Eton Pharmaceuticals has higher revenue and earnings than Anixa Biosciences. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEton Pharmaceuticals$39.01M9.68-$940K-$0.15-93.87Anixa Biosciences$210K421.63-$12.55M-$0.39-7.05 SummaryAnixa Biosciences beats Eton Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Remove Ads Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.54M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-7.056.7221.6917.68Price / Sales421.63223.16371.6292.88Price / CashN/A65.6738.1534.64Price / Book4.665.776.373.94Net Income-$12.55M$142.23M$3.20B$247.45M7 Day Performance2.23%2.72%1.67%0.48%1 Month Performance-7.09%-14.04%-9.49%-7.08%1 Year Performance-13.25%-12.31%9.59%-0.35% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences2.8968 of 5 stars$2.75-3.5%$9.00+227.3%-9.8%$88.54M$210,000.00-7.055Gap DownETONEton Pharmaceuticals2.2549 of 5 stars$11.85+0.2%$27.67+133.5%+340.7%$317.79M$39.01M-53.8620Short Interest ↑Gap UpHigh Trading VolumeALLOAllogene Therapeutics2.9534 of 5 stars$1.43-0.7%$9.29+549.6%-58.9%$310.69M$22,000.00-0.92310TRDAEntrada Therapeutics3.1079 of 5 stars$8.19+3.1%$25.67+213.4%-38.9%$307.90M$210.78M5.15110News CoveragePositive NewsAMLXAmylyx Pharmaceuticals2.878 of 5 stars$3.46+0.9%$8.00+131.2%+87.4%$306.56M$87.37M-0.91200Analyst RevisionNews CoverageALTAltimmune2.6656 of 5 stars$3.98-6.1%$20.83+423.5%-40.0%$306.52M$20,000.00-2.5750Gap UpHRTXHeron Therapeutics3.4984 of 5 stars$1.96-6.7%$5.67+189.1%-34.9%$298.57M$144.29M-10.89300Positive NewsRGNXREGENXBIO4.7158 of 5 stars$5.93-5.7%$32.78+452.7%-63.7%$297.01M$83.33M-1.18370Positive NewsGap UpVERVVerve Therapeutics2.9256 of 5 stars$3.34-7.7%$20.67+518.8%-32.0%$296.58M$32.33M-1.36110Analyst ForecastOptions VolumeNews CoverageGap DownHigh Trading VolumeTECXTectonic Therapeutic2.7817 of 5 stars$15.53-0.6%$77.75+400.6%N/A$289.84MN/A-2.64120Short Interest ↑Positive NewsGap DownORKAOruka Therapeutics3.1168 of 5 stars$7.62-2.7%$39.86+423.1%N/A$285.30MN/A-1.22N/ANews CoveragePositive NewsGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Eton Pharmaceuticals Alternatives Allogene Therapeutics Alternatives Entrada Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Altimmune Alternatives Heron Therapeutics Alternatives REGENXBIO Alternatives Verve Therapeutics Alternatives Tectonic Therapeutic Alternatives Oruka Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
